Latest news with #undervalued
Yahoo
4 hours ago
- Business
- Yahoo
H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL), Sets a $57 PT
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the top most undervalued biotech stocks to buy now. On August 6, analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) with a $57.00 price target. A researcher in a lab coat monitoring a biotechnological experiment. The analyst based the positive rating on the company's promising growth outlook and solid financial performance, stating that Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) reported an EPS of $3.28 in fiscal Q2 2025, exceeding both the firm's estimate of $2.52 and the consensus of $1.40. The company also surpassed expectations by reporting $101.7 million in total revenue in the quarter, attributed primarily to higher-than-expected revenue from Tavalisse. The analyst reasoned that Tavalisse benefited from enhanced access and higher patient starts after changes in Medicare Part D coverage. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a clinical-stage biotechnology company that discovers and develops targeted, novel drugs in oncology, immunology, and immune oncology. Its product portfolio includes Tavalisse, Fostamatinib, and R835. While we acknowledge the potential of RIGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
4 hours ago
- Business
- Yahoo
J.P. Morgan Maintains a Buy Rating on Newell Brands (NWL), Sets a $7 PT
Newell Brands Inc. (NYSE:NWL) is one of the best undervalued defensive stocks to buy according to analysts. In a report released on August 1, Andrea Faria Teixeira from J.P. Morgan maintained a Buy rating on Newell Brands Inc. (NYSE:NWL) with a price target of $7.00. A technician inspecting a commercial kitchen appliance in a factory line. The analyst told investors in a research note that, despite the recent guidance cut, they believe that the worst is possibly behind Newell Brands Inc. (NYSE:NWL) and the current market opportunity presents a buying opportunity. Teixeira added that Newell Brands Inc. (NYSE:NWL) has exhibited resilience by expanding margins in seven consecutive quarters, driven by a focus on operating expense rationalization and cost-cutting measures. Newell Brands, Inc. (NYSE:NWL) is a global consumer goods company that manufactures, markets, and sells consumer and commercial products. Its Home and Commercial Solutions segment offers commercial cleaning and maintenance solutions, hygiene systems, garage and closet organization products, and others. While we acknowledge the potential of NWL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
4 hours ago
- Business
- Yahoo
Oppenheimer Slashes PT on Spectrum Brands Holdings (SPB) to $95 From $105
Spectrum Brands Holdings, Inc. (NYSE:SPB) is one of the best undervalued defensive stocks to buy according to analysts. On August 8, Oppenheimer lowered the firm's price target on Spectrum Brands Holdings, Inc. (NYSE:SPB) to $95 from $105 while keeping an Outperform rating on the shares. A person enjoying the convenience of their pet products, that simplify clean-up. The firm told investors in a research note that Spectrum Brands Holdings, Inc.'s (NYSE:SPB) Q3 EBITDA of $77M compares to its/Street's $90M/$81M estimates, attributed to softer demand in HPC and GPC and tariff-related supply constraints. Oppenheimer also stated that while tariffs and reduced inventory considerably affected Q3, the businesses delivered higher sales rates in July. The firm added that Spectrum Brands Holdings, Inc. (NYSE:SPB) had mostly removed tariff exposure by the end of Q3 with initial rounds of pricing and supplier concessions. Spectrum Brands Holdings, Inc. (NYSE:SPB) is a global manufacturer of branded home essentials and consumer products. The company manufactures, sells, and markets its products across Europe, the Middle East and Africa, North America, Latin America, and the Asia-Pacific regions. While we acknowledge the potential of SPB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Business
- Yahoo
TD Cowen Maintains a Hold Rating on MGP Ingredients (MGPI) With a $30 PT
MGP Ingredients, Inc. (NASDAQ:MGPI) is one of the best undervalued defensive stocks to buy according to analysts. Analyst Robert Moskow from TD Cowen maintained a Hold rating on MGP Ingredients, Inc. (NASDAQ:MGPI) on August 1, keeping the price target at $30.00. A close-up of an iconic bottle of branded spirit produced by the distillery. The analyst told investors in a research note that MGP Ingredients, Inc. (NASDAQ:MGPI) exhibited strong Q2 results that surpassed consensus but aligned with internal expectations. Management reaffirmed its 2025 guidance, but the forecast still expects a considerable decline in gross profit despite proactive contract negotiations offering better visibility with Brown Goods customers. Moskow added that Branded Spirits sales have exhibited weakness, especially with the mid and value segments experiencing a considerable decline. He expects this trend to continue, with sales estimated to decline further by 2025. MGP Ingredients, Inc. (NASDAQ:MGPI) manufactures and trades food, beverages, starch food ingredients, and specialty wheat protein. The company's operations are divided into the following segments: Distilling Solutions, Branded Spirits, and Ingredient Solutions. While we acknowledge the potential of MGPI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
4 hours ago
- Business
- Yahoo
H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the top most undervalued biotech stocks to buy now. On August 6, H.C. Wainwright analyst Mitchell Kapoor raised the firm's price target on Halozyme Therapeutics, Inc. (NASDAQ:HALO) to $75 from $72, keeping a Buy rating on the shares. An image of a research technician wearing lab coat with a syringe full of biopharmaceuticals. The rating update came after Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported its fiscal Q2 2025 results. The analyst told investors in a research note that Halozyme Therapeutics, Inc. (NASDAQ:HALO) raised its fiscal 2025 guidance for the third time this year following another quarter of solid results. Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported its fiscal Q2 2025 results on August 5, with total revenue increasing 41% year-over-year to $326 million and royalty revenue growing 65% year-over-year to $206 million. Net income for the quarter rose 77% year-over-year to $165 million, while adjusted EBITDA increased 65^ year-over-year to $226 million. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that develops, manufactures, and commercializes drug-device combination products through advanced auto-injector technology. They offer commercial or functional benefits, including increased patient comfort and adherence, and enhanced tolerability and convenience. While we acknowledge the potential of HALO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
